Cargando…

PR1 Peptide Vaccine Induces Specific Immunity With Clinical Responses In Myeloid Malignancies

PR1, an HLA-A2-restricted peptide derived from both proteinase 3 and neutrophil elastase, is recognized on myeloid leukemia cells by cytotoxic T lymphocytes (CTL) that preferentially kill leukemia and contribute to cytogenetic remission. To evaluate safety, immunogenicity and clinical activity of PR...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qazilbash, Muzaffar H., Wieder, Eric, Thall, Peter F., Wang, Xuemei, Rios, Rosa, Lu, Sijie, Kanodia, Shreya, Ruisaard, Kathryn E., Giralt, Sergio A., Estey, Elihu H., Cortes, Jorge, Komanduri, Krishna V., Clise-Dwyer, Karen, Alatrash, Gheath, Ma, Qing, Champlin, Richard E., Molldrem, Jeffrey J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5332281/ https://www.ncbi.nlm.nih.gov/pubmed/27654852 http://dx.doi.org/10.1038/leu.2016.254

Ejemplares similares

PR1-Specific T Cells Are Associated with Unmaintained Cytogenetic Remission of Chronic Myelogenous Leukemia After Interferon Withdrawal
por: Kanodia, Shreya, et al.
Publicado: (2010)

Targeting PR1 in myeloid leukemia
por: Alatrash, Gheath, et al.
Publicado: (2017)

Activity of 8F4, a T cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo
por: Sergeeva, Anna, et al.
Publicado: (2016)

A Novel T-Cell Engaging Bi-specific Antibody Targeting the Leukemia Antigen PR1/HLA-A2
por: Herrmann, Amanda C., et al.
Publicado: (2019)

Cathepsin G Is Expressed by Acute Lymphoblastic Leukemia and Is a Potential Immunotherapeutic Target
por: Khan, Maliha, et al.
Publicado: (2018)

Targeting cathepsin G in myeloid leukemia
por: Alatrash, Gheath
Publicado: (2013)

Common Minor Histocompatibility Antigen Discovery Based upon Patient Clinical Outcomes and Genomic Data
por: Armistead, Paul M., et al.
Publicado: (2011)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Immune checkpoints: A therapeutic target in triple negative breast cancer
por: Chawla, Akhil, et al.
Publicado: (2014)

Adoptive T-cell therapy for Leukemia
por: Garber, Haven R, et al.
Publicado: (2014)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

New Cancer Therapies: Implications for the Perioperative Period
por: Andrabi, Tayab, et al.
Publicado: (2018)

Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
por: Wallis, Whitney D, et al.
Publicado: (2017)

Impact of renal impairment on light chain amyloidosis outcomes after autologous hematopoietic stem cell transplantation
por: Srour, Samer A., et al.
Publicado: (2020)

Delta-24-RGD Oncolytic Adenovirus Elicits Anti-Glioma Immunity in an Immunocompetent Mouse Model
por: Jiang, Hong, et al.
Publicado: (2014)

A myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA-matched and haploidentical transplantation: results of a phase II study
por: Popat, Uday R., et al.
Publicado: (2022)

Allogeneic Hematopoietic Cell Transplantation for Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
por: Bashir, Qaiser, et al.
Publicado: (2022)

A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin’s lymphomas
por: Hosing, Chitra, et al.
Publicado: (2010)

CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia
por: Pasvolsky, Oren, et al.
Publicado: (2022)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Isolation, culture, and immunophenotypic analysis of bone marrow HSPCs from patients with myelodysplastic syndromes
por: Ganan-Gomez, Irene, et al.
Publicado: (2022)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

Steroid-Refractory Acute GVHD: Predictors and Outcomes
por: Westin, Jason R., et al.
Publicado: (2011)

Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial
por: Malek, Ehsan, et al.
Publicado: (2023)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target
por: Alatrash, Gheath, et al.
Publicado: (2016)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies
por: Bal, Susan, et al.
Publicado: (2023)

Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
por: Mehta, Rohtesh S., et al.
Publicado: (2021)

Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities
por: Popat, Uday R., et al.
Publicado: (2023)

Navigating the Intersection of PrEP and Medicaid
por: Seiler, Naomi, et al.
Publicado: (2022)

Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant
por: Nieto, Yago, et al.
Publicado: (2023)

Fucosylation enhances activity of cytotoxic T lymphocytes against breast cancer
por: Qiao, Na, et al.
Publicado: (2015)

P1270: MYELOABLATIVE FRACTIONATED BUSULFAN-BASED CONDITIONING REGIMEN IN PATIENTS WITH AML AND MDS: RESULTS OF A RANDOMIZED CLINICAL TRIAL COMPARING 2 FRACTIONATION SCHEDULES
por: Popat, Uday R., et al.
Publicado: (2023)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial
por: Shah, J J, et al.
Publicado: (2016)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_376qbcgsh03ukfsbr5gb167ff7